MarketPulse

licensing agreement

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Biocryst Pharmaceuticals, Inc.

BioCryst Lands $70M Deal, Reports ORLADEYO Growth Ahead of Navenibart Catalyst

BioCryst posts 11% ORLADEYO revenue growth to $148.3M in Q1 2026, inks $70M European licensing deal for navenibart with up to $275M in milestones.
BCRXrevenue growthclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Snail Games Pivots Beyond ARK With New Releases, Cost Cuts Fueling Expansion

Snail Inc. launches Survivor Mercs, develops three AAA titles for 2027, and cuts licensing costs by $6M to fund diversification strategy.
SNALlicensing agreementindependent game publisher
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Snail Games Pivots Beyond ARK, Launches Survivor Mercs While Cutting Licensing Costs

Snail, Inc. launches Survivor Mercs in April 2026 across major platforms while pursuing diversification strategy with multiple new titles and $6M licensing fee reduction.
SNALcost reductionlicensing agreement
BenzingaBenzinga··Prnewswire

CETI Fields $200M African Power Order as Clean Energy Licensing Deal Gains Traction

Cyber Enviro-Tech receives initial inquiry for 85 AirPower systems in Africa valued near $200M, marking early commercial success following recent licensing agreement.
CETIclean energylicensing agreement
BenzingaBenzinga··Vandana Singh

Nanobiotix Shoots Down J&J Acquisition Rumors, Stock Soars on Clarity

Nanobiotix denies J&J acquisition rumors, shares rise 6.17%. Stock up 774.83% annually; reaffirms focus on advancing cancer pipeline, NBTXR3 partnership.
JNJNBTXcancer treatmentbiotechnology
BenzingaBenzinga··Bamboo Works

Jacobio Pharma Eyes 2026 Profitability on AstraZeneca Deal and Cancer Drug Sales

Chinese biotech Jacobio Pharmaceuticals expects profitability in 2026 via $100M AstraZeneca deal for KRAS inhibitor and growing Glecirasib sales.
AZNprofitabilitylicensing agreement
GlobeNewswire Inc.GlobeNewswire Inc.··Na

EssilorLuxottica Locks in D&G Through 2050 With Quarter-Century Extension

EssilorLuxottica extends Dolce&Gabbana eyewear licensing deal through 2050, securing 25-year partnership for frames design, production, and global distribution.
ESLOYlicensing agreementlong-term partnership
GlobeNewswire Inc.GlobeNewswire Inc.··Na

EssilorLuxottica Locks In D&G Through 2050 in Historic Eyewear Deal

EssilorLuxottica extends Dolce&Gabbana eyewear licensing deal through 2050, cementing a 46-year partnership with a major luxury fashion house.
ESLOYlicensing agreementpartnership extension
GlobeNewswire Inc.GlobeNewswire Inc.··Na

JAKKS Pacific Secures Major Anime Merchandise Deal with Crunchyroll

JAKKS Pacific partners with Crunchyroll to develop and distribute anime merchandise for five major franchises including My Hero Academia and Chainsaw Man across U.S. retail channels.
JAKKpartnershipanime merchandise
BenzingaBenzinga··Vandana Singh

Eli Lilly's Dual-Therapy Approach Demonstrates Enhanced Efficacy in Psoriasis-Obesity Treatment

Eli Lilly's combo therapy of Taltz and Zepbound showed superior results for psoriasis-obesity patients, achieving 27.1% complete skin clearance versus 5.8% for monotherapy.
LLYCSLLYPhase 3b trialZepbound